Injectable Magnetic-Nanozyme Based Thermosensitive Hydrogel for Multimodal DLBCL Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a challenging non-Hodgkin lymphoma due to treatment resistance and immunosuppression.
• Conventional therapies often fail to overcome chemoresistance and metastatic progression in DLBCL.

Purpose of the Study:

• To develop and evaluate a novel injectable hydrogel system for treating DLBCL.
• To investigate the synergistic effects of magnetothermal therapy (MHT), chemodynamic therapy (CDT), and immunomodulation.

Main Methods:

• An injectable Fe3O4@DMSA@Pt@PLGA-PEG-PLGA hydrogel system was designed.
• The system integrates MHT, CDT, and immunomodulation under alternating magnetic fields (AMF).
• Cancer cell apoptosis, immunogenic cell death (ICD) markers, dendritic cell maturation, and T cell activation were assessed.

Main Results:

• The hydrogel system rapidly achieved therapeutic hyperthermia (50 °C in 7 min) and enhanced ROS generation via MHT and CDT.
• Significant apoptotic cell death (75.9%) was observed in DLBCL cells, exceeding CDT alone.
• The treatment induced ICD, robust dendritic cell maturation, and T cell activation.

Conclusions:

• The magnetothermal-chemodynamic synergistic hydrogel shows significant therapeutic potential against DLBCL.
• This multi-mechanism approach offers a promising strategy for DLBCL treatment with potential for clinical translation.